[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100649911":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":30,"centralContacts":35,"locations":40,"responsibleParty":54,"collaborators":25,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":25,"eligibilityCriteria":62,"healthyVolunteers":58,"sex":63,"minAge":64,"maxAge":25,"enrollmentInfo":65,"targetDuration":25,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":74,"overallStatus":79,"whyStopped":25,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"Chinese University of Hong Kong","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Surgical Resection arm","EXPERIMENTAL","Participants undergo surgical resection for treatment of the target pulmonary lesion.",[13],"Procedure: Surgical Resection",{"label":15,"type":10,"description":16,"interventionNames":17},"Bronchoscopic Microwave Ablation Arm","Participants undergo bronchoscopic microwave ablation for treatment of the target pulmonary lesion.",[18],"Procedure: Bronchoscopic Microwave Ablation",[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"PROCEDURE","Bronchoscopic Microwave Ablation","The study doctor perform robotic-assisted or electromagnetic navigation bronchoscopy to locate the target lung lesion, deliver the ablation catheter through the bronchus to the target site for lesion puncture, and conduct microwave ablation. After the surgery, CBCT scanning is conducted to evaluate the ablation effect, and repeated ablation is performed as needed.",[15],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Surgical Resection","The study doctor will begin by opening the hilar pleural reflection, followed by dissection of and division of lobar \u002F segmental vein and artery by endostaplers. Segmental or lobar bronchus is dissected out and stapled. Lymphadenectomy will be performed and the specimens will be retrieved using protective bags via utility wound. This lung tissue specimen may also be analysed for research purpose.",[9],[31],{"name":32,"affiliation":33,"role":34},"Calvin Sze Hang Ng","CUHK","PRINCIPAL_INVESTIGATOR",[36],{"name":32,"role":37,"phone":38,"phoneExt":25,"email":39},"CONTACT","852-3505-2618","calvinng@surgery.cuhk.edu.hk",[41],{"facility":42,"status":25,"city":43,"state":25,"zip":25,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"Prince of Wales Hospital","Hong Kong","HK",{"type":46,"coordinates":47},"Point",[48,49],114.17469,22.27832,{"lat":49,"lon":48},[52,53],{"name":32,"role":37,"phone":38,"phoneExt":25,"email":39},{"name":32,"role":34,"phone":25,"phoneExt":25,"email":25},{"type":34,"investigatorFullName":32,"investigatorTitle":55,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"Environmental Foundation Professor of Thoracic Surgery","100649911","phase-2-study-of-robotic-assistedimage-guided-electromagnetic-navigation-bronchoscopic-therapies-and-surgery-in-stage-ia-nsclc-100649911",false,"NCT07741344","Study of Robotic Assisted\u002FImage Guided Electromagnetic Navigation Bronchoscopic Therapies and Surgery in Stage IA NSCLC","A Dual-Phase Study Comparing Survival, Immune Activation, and Functional Preservation Between Robotic-assisted \u002F Image Guided Electromagnetic Navigation Bronchoscopic Therapies and Surgery in Stage IA NSCLC","Bronchoscopic Microwave Ablation Group Inclusion Criteria\n\n1. Adults aged ≥18 years\n2. Histologically or cytologically confirmed stage IA NSCLC (T1N0M0, tumor ≤3 cm)\n3. Determined by multidisciplinary evaluation to be an appropriate candidate for bronchoscopic ablation as part of standard clinical care, and the patient agrees to a lung-preserving treatment approach\n4. Tumour size less than 2.5 cm in maximum diameter as measured on thin-slice chest CT\n5. Tumour located in the middle or peripheral third of the lung parenchyma\n6. Imaging and clinical evaluation indicate no lymph node involvement, and lymph node dissection for staging is not required\n7. Medically fit for bronchoscopic procedure under standard institutional anaesthesia protocols\n8. Pulmonary function results or clinical assessment indicate significant benefit from preserving lung tissue, such as predicted FEV1 or DLCO less than 40%, or clinician judgment that lung preservation is critical for quality of life\n9. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2\n\nExclusion Criteria\n\n1. Presence of lymph node involvement (N1 or higher) or distant metastases (M1)\n2. Centrally located tumours within the inner third of the lung or those requiring ablation near major airways\n3. Tumours adjacent to heat-sensitive structures (e.g., main bronchi, oesophagus, pericardium, aorta, or pulmonary artery) where adequate ablation margins cannot be safely achieved\n4. Rapidly enlarging lesions or those with high metabolic activity on PET-CT that warrant surgical resection and lymph node evaluation\n5. Imaging findings suggesting possible nodal involvement that necessitate surgical dissection for accurate staging\n6. Pregnant or breastfeeding women\n7. Inability or unwillingness to comply with study procedures\n8. Presence of electronic implants (e.g., pacemaker or defibrillator) at risk of interference from microwave energy\n9. Active pulmonary infection, uncorrectable coagulopathy, or ASA score ≥4\n10. Patients with multiple lesions requiring both surgery and ablation who cannot represent a single treatment strategy within the study\n\nSurgical Resection Group Inclusion Criteria\n\n1. Adults aged ≥18 years\n2. Histologically or cytologically confirmed stage IA NSCLC (T1N0M0, tumor ≤3 cm)\n3. Determined by multidisciplinary evaluation to have surgical resection as the preferred standard treatment option, and patient agrees to surgical resection.\n4. Tumour size between 2.5 and 3.0 cm, or smaller lesions for which surgery is considered the more appropriate option based on tumour features or safety concerns.\n5. Tumour located in the central third of the lung, or in proximity to heat-sensitive structures where surgery offers better oncologic and safety margins.\n6. Imaging findings suggest possible lymph node involvement or a clinical indication for systematic nodal dissection and pathological staging.\n7. Rapidly growing or high-SUV lesions on PET-CT requiring complete resection and full histologic staging.\n8. Medically fit for general anaesthesia and surgical resection, with capability for intraoperative frozen-section margin assessment\n\nExclusion Criteria\n\n1. Presence of lymph node involvement (N1 or higher) or distant metastases (M1)\n2. High surgical risk or limited pulmonary reserve where a lung-preserving strategy is preferred.\n3. Tumours clearly suitable for ablation (≤2.5 cm, located in the middle or peripheral third, and safely ablatable with adequate margins).\n4. Active pulmonary infection, uncorrectable coagulopathy, or unfit for general anaesthesia or lung resection.\n5. Patients with multiple lesions, some requiring surgery and others ablation, who cannot be assigned to a single treatment strategy within the study.\n6. Pregnant or breastfeeding women\n7. Inability or unwillingness to comply with study procedures","ALL","18 Years",{"count":66,"type":67},292,"ESTIMATED","INTERVENTIONAL",[70],"PHASE2","This study aims to address the core deficiencies in the field by situating bronchoscopic ablation within the same evidentiary frame as segmentectomy and lobectomy. It will deliver adjusted retrospective comparisons with external validation using population data, a prospective noninferiority evaluation on disease control and safety, quantitative evidence on pulmonary function and quality of life, and translational endpoints linking circulating tumour DNA (ctDNA) dynamics and immune activation to durability of control. The work is directly aligned with Hong Kong service needs, where a safe lung preserving option that shortens recovery and optimises resource use could relieve surgical waiting pressure while maintaining oncologic outcomes.",[73],"Stage IA NSCLC",[75,76,77,73,78],"Bronchoscopic ablation","Robotic assisted bronchoscopy","Image guided ENB","disease-free survival","NOT_YET_RECRUITING","2026-07-28",{"date":82,"type":83},"2026-08-03","ACTUAL",{"date":85,"type":67},"2026-07-31",{"date":87,"type":67},"2029-12-31",{"name":5,"class":6},1]